Abstract: Methods of treating eosinophilia by down regulating eotaxin and at least one other Th-2 related cytokine are dislosed as are multivalent immunogenic compositions that generate an active immune response in a subjet comprising autoantibodies to eotaxin-1, eotaxin-2, IL-4, IL-5, IL-9, and IL-13 and treatment methods using such compositions.

Abstract: An injectable vaccine composition comprising an immunogenic conjugate in an emulsion containing advantageous oily vehicles is disclosed as suitable for frozen storage; moreover, a water-in-oil emulsion composition is found to enhance immunogenicity after storage at about −18° C.

Abstract: The invention concerns methods for killing antibiotic-resistant pathogenic bacteria responsible for disease in humans and animals. The methods employ a lanthocin such as nisin as bactericidal agent.

Abstract: Lysostaphin is used to eliminate and cure staphylococcal infections including the cure of mastitis by intramammary infusion. Administration of from 2 mg to 400 mg of lysostaphin to an infected bovine mammary gland eliminates staphylococci, and the reoccurrence common with antibiotic therapy is not observed. Teat-dips containing lysostaphin, mutanolysin and lysozyme can be used as a prophylactic. Synergistic enhancement of the killing effect of lysostaphin is observed when a mild surfactant or penicillin or both is included in the formulation.

Abstract: A method and apparatus for storing compressed file data stored on a disk. The method includes an improved format for the Compressed Volume File (CVF), and more specifically, 10 an improved format for the MDFAT data structure stored within the CVF. The improved format includes using an additional byte for maintaining each entry in the MDFAT data structure which increases the number of sectors within the Sector Heap that can be addressed and accessed. The improved format further allows compressed clusters to be stored in fragments in various portions of vacant storage space located throughout the Sector Heap. The new format for the MDFAT data structure includes a bit that identifies whether each cluster is being stored in fragments. The method stores the locations of each of the fragments in a Fragment Pointer List located in the first sector of the first fragment.

Abstract: Disclosed are compositions of nisin and GML as active ingredients for the killing of Helicobacter, as well as methods for eradicating Helicobacter colonization and treatment of Helicobacter infection which employ the GML/nisin compositions.

Abstract: The invention concerns compositions containing a lanthionine containing bacteriocin such as nisin which are stabilized by the presence of a thioether stabilizing agent against degradation.

Abstract: Disclosed are novel, moist paper or fabric wipes containing a bacteriocin disinfectant formulation, which have a low alcohol content and which afford rapid, one-step disinfection and drying of surfaces. Also disclosed is a method of disinfection and drying of skin, including cow teat skin, either prior to or after milking, which employs the wipes.

Abstract: Lysostaphin is used to eliminate and cure staphylococcal infections including the cure of mastitis by intramammary infusion. Administration of from 2 mg to 400 mg of lysostaphin to an infected bovine mammary gland eliminates staphylococci, and the reoccurrence common with antibiotic therapy is not observed. Teat-dips containing lysostaphin, mutanolysin and lysozyme can be used as a prophylactic. Synergistic enhancement of the killing effect of lysostaphin is observed when a mild surfactant or penicillin or both is included in the formulation.

Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.

Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.

Abstract: Compositions comprising lanthionine-containing bacteriocins such as nisin in combination with a chelator act as bactericides in low pH environments. In a preferred embodiment pharmaceutical preparations containing the compositions are used for the control of bacteria responsible for disorders of the gastrointestinal tract.

Abstract: Compositions comprising lanthionine-containing bacteriocins such as nisin act as bactericides under conditions such as those found in the gastrointestinal tract. In a preferred embodiment pharmaceutical preparations containing the compositions are used for the control of bacteria responsible for disorders of the gastrointestinal tract.

Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.

Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.

Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.

Abstract: Broad range bacteriocin compositions are provided. The compositions can be dissolved or suspended in a suitable solvent or matrix and are more active towards a broader range of bacteria than are any of the component parts. The dissolved or suspended compositions constitute enhanced broad range bactericides. The compositions include lysostaphin and a lanthionine containing peptide bacteriocin; lysostaphin, a lanthionine containing peptide bacteriocin and a chelating agent; and lysostaphin, a lanthionine containing peptide, a chelating agent and a surfactant. Each component is present in the enhanced broad range bactericide in sufficient amount such that the bactericide is more effective against staphylococci than is lysostaphin alone and is more effective at treating and preventing a broad range of microbial infections. Methods of treating bacterial infections using said compositions and bactericides are provided.